FindTrial
Sign In

Taurine in Peripartum Cardiomyopathy

Taurine for Early Left Ventricular Recovery in Peripartum Cardiomyopathy

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03907267
Enrollment
40
Registered
2019-04-08
Start date
2015-01-01
Completion date
2020-01-01
Last updated
2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripartum Cardiomyopathy

Brief summary

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Interventions

DRUGTaurine Solution

Taurine Solution

DIETARY_SUPPLEMENTNormal Saline

Normal Saline

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Peripartum Cardiomyopathy

Exclusion criteria

* Other identifiable cause for heart failure * low LVEF ≤ 25% * sepsis * autoimmune disease * severe chronic disease * malignancy

Design outcomes

Primary

MeasureTime frameDescription
improvement of the left ventricular ejection fraction >10 %1 weekimprovement of the left ventricular ejection fraction \>10 %

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026